Multi-cancer early detection liquid biopsy (ctDNA)

The evidence base is commercial rather than outcome-proven. No multi-cancer early detection assay has published randomised controlled trial evidence that screening reduces cancer mortality. The largest trial, NHS-Galleri, has a published design paper only; its primary endpoint is the incidence of stage III and IV cancers at 3 to 4 years, and the authors state plainly that the trial "was not primarily powered to assess mortality reduction, as it would likely require at least 6 years follow-up." The same paper flags the relevant cautionary precedent from ovarian cancer screening, where a 10.2% reduction in late-stage incidence attenuated to a non-significant 4.4% reduction in disease-specific mortality, so a stage-shift result would not by itself establish benefit. Material harms are not hypothetical: because these tests are applied to asymptomatic populations with low pre-test probability, even high specificity yields a meaningful absolute number of false positives, each triggering a diagnostic workup (imaging, biopsy, sometimes invasive procedures) with its own cost, risk and anxiety. Overdiagnosis of indolent disease is a further unquantified harm. A negative result also carries no assurance, since sensitivity is low for early-stage disease across all assays. Two corrections to the discovery brief are worth recording. First, the Singapore offering is Lucence, not GRAIL's Galleri; I found no retrieved source confirming Galleri is commercially available in Singapore, and the marketed "up to 50 cancer types" figure applies only to the top LucenceINSIGHT 50 tier (SGD 3,800), not to the LucenceINSIGHT Core (SGD 600) bundled into NOVI's assessment, which covers six cancers. Second, on clinics: I verified NOVI Health directly from its own site. Mount Elizabeth is reported to offer a Multi-Cancer Early Detection Screen using LucenceINSIGHT, but its site returned HTTP 403 to every retrieval attempt, so I have not confirmed it and have deliberately left it out of offeredBy. DA MedSuites (Doctor Anywhere) was verified as naming LucenceINSIGHT in its top-tier Sequoia package but is not on the supplied clinic list. I found no evidence of MCED liquid biopsy at any named Australian clinic, and SPOT-MAS was not verified in either market. Two caveats on this research pass: the session's web search budget was fully exhausted before I began, so I could work only from direct URL retrieval, and both the HSA and TGA sites failed to return content (timeouts and blocks). Regulatory status is therefore null in both markets, not because it is unknowable but because I could not reach an authoritative source, and it should be re-verified before publication.

What it is

Plain-language explainer

Categories